The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01897571




Registration number
NCT01897571
Ethics application status
Date submitted
21/06/2013
Date registered
12/07/2013
Date last updated
9/07/2019

Titles & IDs
Public title
Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL
Scientific title
An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma
Secondary ID [1] 0 0
E7438-G000-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
B-cell Lymphomas (Phase 1) 0 0
Advanced Solid Tumors (Phase 1) 0 0
Diffuse Large B-cell Lymphoma (Phase 2) 0 0
Follicular Lymphoma (Phase 2) 0 0
Transformed Follicular Lymphoma 0 0
Primary Mediastinal Large B-Cell Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Tazemetostat

Experimental: Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 1 - This portion comprises dose escalation and dose expansion to establish the recommended Phase 2 dose (RP2D) when tazemetostat is given BID (twice daily) orally on a continuous basis. Additionally, in separate cohorts in Phase 1, the effect of food on the bioavailability of tazemetostat as well as the drug-drug interaction (DDI) potential of tazemetostat are evaluated. CLOSED TO ENROLLMENT

Experimental: Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 2 - This portion is restricted to subjects with DLBCL or FL for the determination of efficacy and safety of tazemetostat monotherapy and tazemetostat in combination with prednisolone as defined by histology, cell of origin and EZH2 mutation status.


Treatment: Drugs: Tazemetostat


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Maximum tolerated dose (MTD) (Phase 1 only) - To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of tazemetostat as a single agent administered orally twice daily (BID), continuously in 28-day cycles in subjects with advanced solid tumors or with relapsed and/or refractory B cell lymphomas
Timepoint [1] 0 0
28 day cycle of therapy
Primary outcome [2] 0 0
Objective response rate (ORR; complete response + partial response [CR + PR]) (Phase 2) - To determine the objective response rate (ORR; complete response + partial response [CR + PR]) of tazemetostat in subjects with enhancer of zeste homolog 2 (EZH2) gene mutation positive or negative (wild-type) with histologically confirmed diffuse large B cell lymphoma (DLBCL) or follicular lymphoma (FL), with relapsed or refractory disease and the ORR of tazemetostat in combination with prednisolone in subjects with EZH2 wild-type DLBCL
Timepoint [2] 0 0
Every 8 weeks or sooner, if clinically indicated, until documentation of disease.
Secondary outcome [1] 0 0
The effect of a high fat meal on the bioavailability of tazemetostat (Phase 1)
Timepoint [1] 0 0
28 day cycle of therapy
Secondary outcome [2] 0 0
The effect of tazemetostat on exposure of midazolam, a CYP3A4 substrate
Timepoint [2] 0 0
28 day cycle of therapy
Secondary outcome [3] 0 0
To assess the preliminary activity of tazemetostat (Phase 1)
Timepoint [3] 0 0
28 day cycle of therapy
Secondary outcome [4] 0 0
The effect of tazemetostat monotherapy and tazemetostat in combination with prednisolone on progression-free survival (PFS) (Phase 2)
Timepoint [4] 0 0
From date of enrollment until the date of first documented progression of disease, or date of death from any cause
Secondary outcome [5] 0 0
The effect of tazemetostat monotherapy and tazemetostat in combination with prednisolone on duration of response (DOR) (Phase 2)
Timepoint [5] 0 0
From date of enrollment until the date of first documented progression of disease, or date of death from any cause
Secondary outcome [6] 0 0
The safety and tolerability of tazemetostat monotherapy and tazemetostat in combination with prenisolone (Phase 1 and Phase 2)
Timepoint [6] 0 0
28 day cycle of therapy
Secondary outcome [7] 0 0
The pharmacokinetic (PK) profile of tazemetostat monotherapy and tazemetostat in combination with prednisolone (Phase 1 and Phase 2)
Timepoint [7] 0 0
28 day cycle of therapy
Secondary outcome [8] 0 0
The effect of tazemetostat monotherapy and tazemetostat in combination with prednisolone on overall survival (OS)
Timepoint [8] 0 0
From the date of first dose until the date of death from any cause.

Eligibility
Key inclusion criteria
Inclusion Criteria

All Subjects:

1. Phase 1: Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

Phase 2: ECOG performance status of 0 to 2.

2. Life expectancy = 3 months before starting tazemetostat.

3. Subjects with Hepatitis B or C are eligible on the condition that subjects have
adequate liver function as defined by Inclusion Criterion #6 and are hepatitis B
surface antigen negative and/or have undetectable hepatitis C virus (HCV) RNA.

4. Adequate renal function defined as calculated creatinine clearance greater than or
equal to 40 mL/min per the Cockcroft and Gault formula or the local institutional
standard formula.

5. Adequate bone marrow function:

1. Absolute neutrophil count (ANC) =750/mm3 (=0.75 x 10^9/L) - Without growth factor
support (filgrastim or pegfilgrastim) for at least 14 days

2. Platelets greater = 75,000/mm3 (=75 x 10^9/L) - Evaluated after at least 7 days
since last platelet transfusion

3. Hemoglobin greater than or equal to 9.0 g/dL - May receive transfusion

6. Adequate liver function:

1. Total bilirubin less than or equal to 1.5 x the upper limit of normal (ULN)
except for unconjugated hyperbilirubinemia of Gilbert's syndrome

2. Alkaline phosphatase (ALP) (in the absence of bone disease), alanine
aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal
to 3 x ULN (less than or equal to 5 x ULN if subject has liver metastases)

7. Time between prior anticancer therapy and first dose of tazemetostat as below:

a. Cytotoxic chemotherapy - At least 21 days b. Non-cytotoxic chemotherapy (eg. Small
molecule inhibitor) - At least 14 days c. Nitrosoureas - At least 6 weeks d.
Monoclonal antibody (ies) - At least 28 days e. Radiotherapy- At least 14 days from
local site radiation therapy/At least 6 weeks from prior radioisotope therapy/At least
12 weeks from 50% pelvic or total body irradiation f. High dose therapy with
autologous hematopoietic cell infusion - At least 60 days g. High dose therapy with
allogeneic transplant - At least 90 days (if graft versus host disease [GVHD] is
present, must be < Grade 2) and no prohibited medications per
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria #3)

Note: Starting at Cycle 1 Day 1, subjects may receive no more than 10 mg of prednisone
daily (or equivalent corticosteroid, excluding protocol-defined prednisolone dosing
for subjects enrolled in Cohort 6) when used for treatment of lymphoma related
symptoms, with the intent to taper by the end of Cycle 1.

8. Males or females aged = 18 years at the time of informed consent (Phase 2). Males and
females aged = 16 years at time of informed consent (Phase 1).

9. Females must not be lactating or pregnant at screening or baseline (as documented by a
negative beta-human chorionic gonadotropin [beta-hCG] test with a minimum sensitivity
of 25 IU/L or equivalent units of beta-hCG). A separate baseline assessment is
required if a negative screening pregnancy test was obtained more than 72 hours before
the first dose of study drug. All females will be considered to be of childbearing
potential unless they are postmenopausal (at least 12 months consecutive amenorrheic,
in the appropriate age group, and without other known or suspected cause) or have been
sterilized surgically (ie, bilateral tubal ligation, total hysterectomy or bilateral
oophorectomy, all with surgery at least 1 month before dose). Females of childbearing
potential must not have had unprotected sexual intercourse within 30 days prior to
study entry and must agree to use a highly effective method of contraception, from the
last menstrual period prior to randomization, during Treatment Cycles, and for 30 days
after the last final dose of study treatment, and have a male partner who uses a
condom. Highly effective contraception includes:

a. Double barrier methods of contraception such as condom plus diaphragm or
cervical/vault cap with spermicide.

b. Placement of an intrauterine device. c. Established hormonal contraceptive methods:
oral, injectable, or implant. Females who are using hormonal contraceptives must have
been on a stable dose of the same hormonal contraceptive product for at least 4 weeks
prior to dosing and must continue to use the same contraceptive during the study and
for 30 days after study drug discontinuation.

Female subjects exempt from this requirement are subjects who practice total
abstinence or have a male partner who is vasectomized. If currently abstinent, the
subject must agree to use a highly effective method of contraception as described
above if they become sexually active during the Treatment Cycles, and for 30 days
after study drug discontinuation.

10. Male subjects must have had a successful vasectomy or they and their female partner
must meet the criteria above (ie, not of childbearing potential or practicing highly
effective contraception and use a condom throughout the study period and for 30 days
after study drug discontinuation).

11. Voluntary agreement to provide written informed consent and the willingness and
ability to comply with all aspects of the protocol.

Phase 1 only:

12. Histologically and/or cytologically confirmed advanced or metastatic solid tumor or
B-cell lymphomas that have progressed after treatment with approved therapies or for
which there are no standard therapies available.

Phase 2 only:

13. Subjects must satisfy all of the following criteria:

1. Have histologically confirmed DLBCL (including primary mediastinal B-cell
lymphoma), with relapsed or refractory disease following at least 2 lines of
prior standard therapy, including alkylator/anthracycline (unless
anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy
(rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
[R-CHOP] or equivalent) AND must be considered unable to benefit from
intensification treatment with autologous hematopoietic stem cell transplantation
(ASCT) as defined by meeting at least 1 of the following criteria:

- Relapsed following, or refractory to, previous ASCT

- Did not achieve at least a partial response to a standard salvage regimen
(eg, rituximab, ifosfamide, carboplatin, and etoposide phosphate [R-ICE] or
rituximab, dexamethasone, cytarabine, and cisplatin [R-DHAP])

- Ineligible for intensification treatment due to age or significant
comorbidity

- Ineligible for intensification treatment due to failure to mobilize an
acceptable number of hematopoietic stem cells

- Refused intensification treatment and/or ASCT or b .Have histologically
confirmed FL, all grades. Subjects may have relapsed/refractory disease
following at least 2 standard prior systemic treatment regimens where at
least 1 anti-CD20-based regimen was used. Subjects with prior radiotherapy
will be included; however, radiotherapy alone will not be considered a
systemic treatment regimen.

c. Have provided sufficient archival tumor tissue that has been successfully tested
for EZH2 mutation status and cell of origin (DLBCL only) at study specific
laboratories allowing for allocation into an open cohort.

d. Have measurable disease as defined by International Working Group-Non-Hodgkin's
Lymphoma (IWG-NHL [Cheson, 2007]).

Exclusion Criteria

All Subjects:

1. Prior exposure to tazemetostat or other inhibitor(s) of EZH2.

2. Subjects with leptomeningeal metastases or brain metastases or history of previously
treated brain metastases.

3. Has thrombocytopenia, neutropenia, or anemia of Grade =3 (per CTCAE 4.03 criteria) and
any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS).

4. Has a prior history of T-cell lymphoblastic lymphoma(T-LBL) or T-cell lymphoblastic
leukemia (T-ALL).

5. Subjects taking medications that are known potent CYP3A4 inducers/inhibitors
(including St. Johns Wort) (see
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteracti
onsLabeling/ucm080499.htm; http://medicine.iupui.edu/clinpharm/ddis/)

6. Subjects unwilling to remove Seville oranges, grapefruit juice and grapefruit from
their diet.

7. Any prior treatment-related (i.e. chemotherapy, immunotherapy, radiotherapy)
clinically significant toxicities have not resolved to = Grade 1 per CTCAE version
4.03 or prior treatment-related toxicities are clinically unstable and clinically
significant at time of enrollment.

8. Major surgery within 4 weeks before the first dose of study drug.

Note: Minor surgery (eg. minor biopsy of extracranial site, central venous catheter
placement, shunt revision) is permitted within 3 weeks prior to enrollment.

9. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled
gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the
bioavailability of tazemetostat.

10. Significant cardiovascular impairment: history of congestive heart failure greater
than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension,
unstable angina, myocardial infarction, or stroke within 6 months of the first dose of
study drug; or cardiac ventricular arrhythmia.

11. Prolongation of corrected QT interval using Fridericia's formula (QTcF) to > 480 msec.

12. Venous thrombosis or pulmonary embolism within the last 3 months before starting
tazemetostat.

13. Active infection requiring systemic therapy.

14. Known hypersensitivity to any component of tazemetostat, prednisolone/prednisone
(combination cohort only), or inability to be treated with a Pneumocystis prophylaxis
medication (combination cohort only).

15. Immunocompromised patients, including patients known to be infected with human
immunodeficiency virus (HIV).

16. Any other major illness that, in the investigator's judgment, will substantially
increase the risk associated with the subject's participation in this study.

17. Females who are pregnant or breastfeeding.

18. Subjects who have undergone an organ transplant.

Phase 2 only:

19. Subjects with noncutaneous malignancies other than B-cell lymphomas. Exception:
Subjects with another malignancy who have been disease-free for 5 years, or subjects
with a history of a completely resected non-melanoma skin cancer or successfully
treated in situ carcinoma are eligible.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1/Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Clayton
Recruitment hospital [2] 0 0
- Geelong
Recruitment hospital [3] 0 0
- Melbourne
Recruitment postcode(s) [1] 0 0
- Clayton
Recruitment postcode(s) [2] 0 0
- Geelong
Recruitment postcode(s) [3] 0 0
- Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
United States of America
State/province [9] 0 0
Virginia
Country [10] 0 0
United States of America
State/province [10] 0 0
Washington
Country [11] 0 0
Canada
State/province [11] 0 0
Montreal
Country [12] 0 0
Canada
State/province [12] 0 0
Toronto
Country [13] 0 0
France
State/province [13] 0 0
Bordeaux
Country [14] 0 0
France
State/province [14] 0 0
Caen
Country [15] 0 0
France
State/province [15] 0 0
Creteil
Country [16] 0 0
France
State/province [16] 0 0
Lille
Country [17] 0 0
France
State/province [17] 0 0
Lyon
Country [18] 0 0
France
State/province [18] 0 0
Marseille
Country [19] 0 0
France
State/province [19] 0 0
Montpellier
Country [20] 0 0
France
State/province [20] 0 0
Nantes
Country [21] 0 0
France
State/province [21] 0 0
Paris
Country [22] 0 0
France
State/province [22] 0 0
Pierre Benite
Country [23] 0 0
France
State/province [23] 0 0
Rennes
Country [24] 0 0
France
State/province [24] 0 0
Rouen
Country [25] 0 0
France
State/province [25] 0 0
Villejuif Cedex
Country [26] 0 0
Germany
State/province [26] 0 0
Gottingen
Country [27] 0 0
Germany
State/province [27] 0 0
Muenster
Country [28] 0 0
Italy
State/province [28] 0 0
Bologna
Country [29] 0 0
Italy
State/province [29] 0 0
Napoli
Country [30] 0 0
Poland
State/province [30] 0 0
Krakow
Country [31] 0 0
Poland
State/province [31] 0 0
Lublin
Country [32] 0 0
Poland
State/province [32] 0 0
Poznan
Country [33] 0 0
Poland
State/province [33] 0 0
Warsaw
Country [34] 0 0
Taiwan
State/province [34] 0 0
Taipei City
Country [35] 0 0
Ukraine
State/province [35] 0 0
Chernivtsi
Country [36] 0 0
Ukraine
State/province [36] 0 0
Dnipro
Country [37] 0 0
Ukraine
State/province [37] 0 0
Ivano-Frankivs'k
Country [38] 0 0
Ukraine
State/province [38] 0 0
Kharkiv
Country [39] 0 0
Ukraine
State/province [39] 0 0
Kyiv
Country [40] 0 0
Ukraine
State/province [40] 0 0
Mykolayiv
Country [41] 0 0
Ukraine
State/province [41] 0 0
Uzhgorod
Country [42] 0 0
Ukraine
State/province [42] 0 0
Zaporizhzhya
Country [43] 0 0
Ukraine
State/province [43] 0 0
Zhytomyr
Country [44] 0 0
United Kingdom
State/province [44] 0 0
Glasgow
Country [45] 0 0
United Kingdom
State/province [45] 0 0
London
Country [46] 0 0
United Kingdom
State/province [46] 0 0
Manchester
Country [47] 0 0
United Kingdom
State/province [47] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Epizyme, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a multicenter, open-label, Phase 1/2 study that is being conducted in two parts. The
Phase 1 part (closed to accrual as of January 25, 2016) is comprised of dose escalation and
expansion parts to establish the MTD and/or the recommended Phase 2 dose (RP2D) when
tazemetostat is given BID (twice daily) orally on a continuous basis. Additionally, in
separate cohorts in Phase 1, the effect of food on the bioavailability of tazemetostat as
well as the drug-drug interaction (DDI) potential of tazemetostat are being evaluated. The
Phase 2 part was initiated once the MTD and /or RP2D was established. Phase 2 enrolls
subjects with DLBCL (Cohorts 1-3 and 6) and FL (Cohorts 4 and 5) for the determination of
efficacy and safety of tazemetostat monotherapy (Cohorts 1-5) and of tazemetostat in
combination with prednisolone (Cohort 6) with placement determined by centrally confirmed
histology, cell of origin (COO), and EZH2 mutation status.
Trial website
https://clinicaltrials.gov/show/NCT01897571
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications